Toxicity of cordycepin in combination with the adenosine deaminase inhibitor 2'-deoxycoformycin in beagle dogs

Toxicology and Applied Pharmacology

Volumn 147, Issue 1, 1997, Pages 39-45

  Rodman, Larry E ^a   Farnell, Daniel R ^a   Coyne, John M ^a   Allan, Paula W ^a   Hill, Donald L ^a   Duncan, Kimberly L K ^b   Tomaszewski, Joseph E ^b   Smith, Adaline C ^b   Page, John G ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; CORDYCEPIN; PENTOSTATIN;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BONE MARROW TOXICITY; CONTROLLED STUDY; DIARRHEA; DOG; FOOD INTAKE; GASTROINTESTINAL TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; LYMPHOID TISSUE; NONHUMAN; THROMBOCYTOPENIA; VOMITING;

ANIMALIA; CANIS FAMILIARIS; EMESIS;

EID: 0030693349     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8264     Document Type: Article

References (30)

1. Adamson R. H., Zaharevitz D. W., Johns D. G. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin. Pharmacology. 15:1977;84-89.
2. Agarwal R. P., Sagar S. M., Parks R. E. Jr. Adenosine deaminase from human erythrocytes: Purification and effects of adenosine analogs. Biochem. Pharmacol. 24:1975;693-701.
3. Agarwal R. P., Spector T., Parks R. E. Jr. Tight-binding inhibitors. IV. Inhibition of adenosine deaminase by various inhibitors. Biochem. Pharmacol. 26:1977;359-367.
4. Annino L., Ferrari A., Giona F., Cimino G., Crescenzi S., Cava M. C., Pacchiarotti A., Mandelli F. Deoxycoformycin induces long-lasting remissions in hairy cell leukemia: Clinical and biological results of two different regimens. Leukemia Lymphoma. 14:1994;115-119.
5. Courtney C. L., Hawkins K. L., Rothwell C. E. Subchronic toxicity of pentostatin in Wistar rats. Toxicol. Pathol. 22:1994;519-523.
6. Döhner H., Ho A. D., Thaler J., Stryckmans P., Sonneveld P., de Witte T., Lechner K., Lauria F., Bödewadt-Radzun S., Suciu S., Solbu G., Witt B., Hunstein W., Zittoun R. Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Natl. Cancer Inst. 85:1993;658-662.
7. Glazer R. I. The effects of 2′-deoxycoformycin on the action of cordycepin on nuclear RNA synthesis in regenerating liver. Toxicol. Appl. Pharmacol. 46:1978;191-197.
8. Greenwood M. F., Coleman M. S., Hutton J. J., Lampkin B., Krill C., Bollum F. J., Holland P. Terminal deoxynucleotidyltransferase distribution in neoplastic and hematopoietic cells. J. Clin. Invest. 59:1977;889-899.
9. Grever M. R., Leiby J. M., Kraut E. H., Wilson H. E., Neidhart J. A., Wall R. L., Balcerzak S. P. Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 3:1985;1196-1201.
10. Grogan T. M., Durie B. G. M., Lomen C., Spier C., Wirt D. P., Nagle R., Wilson G. S., Richter L., Vela E., Maxey V., McDaniel K., Rangel C. Delineation of a novel pre-B cell component in plasma cell myeloma: Immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood. 70:1987;932-942.
11. Haggerty G. C., Thomassen R. W., Chengelis C. P. The dog. Animal Models in Toxicology. 1992;Dekker, New York. p. 567-674.
12. Ho A. D., Thaler J., Willemze R., Lauria F., Mandelli F., Stryckmans P., de Cataldo F., Baccarani M., Peetermans M. E., de Witte T., Suciu S., Solbu G., Zittoun R. Pentostatin (2′-deoxycoformycin) for the treatment of lymphoid neoplasms. Cancer Treat. Rev. 17:1990;213-215.
13. Hoffbrand A. V., Ganeshaguru K., Janossy G., Greaves M. F., Catovsky D., Woodruff R. K. Terminal deoxynucleotidyl-transferase levels and membrane phenotypes in diagnosis of acute leukemia. Lancet. 2:1977;520-523.
14. Jagger D. V., Kredich N. M., Gorin A. J. Inhibition of Ehrlich mouse ascites tumor growth by cordycepin. Cancer Res. 21:1961;216-220.
15. Johns D. G., Adamson R. H. Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin. Biochem. Pharmacol. 25:1976;1441-1444.
16. 32in vitro. Biochim. Biophys. Acta. 76:1963;347-353.
17. Koç Y., McCaffrey R. 2′,3′-Dideoxyadenosine killing of TdT-positive cells is due to a trace contaminant. Leukemia. 9:1995;53-57.
18. Koç Y., Urbano A. G., Sweeney E. B., McCaffrey R. Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells. Leukemia. 10:1996;1019-1024.
19. Kraut E. H., Bouroncle B. A., Grever M. R. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood. 68:1986;1119-1122.
20. LePage G. A., Worth L. S., Kimball A. P. Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin. Cancer Res. 36:1976;1481-1485.
21. Long J. C., McCaffrey R. P., Aisenberg A. C., Marks S. M., Kung P. C. Terminal deoxynucleotidyl transferase positive lymphoblastic lymphoma. Cancer. 44:1979;2127-2139.
22. Marks S. M., Baltimore D., McCaffrey R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N. Eng. J. Med. 298:1978;812-814.
23. McCaffrey R., Harrison T. A., Parkman R., Baltimore D. Terminal deoxynucleotidyl transferase activity in human leukemic cells and in normal human thymocytes. N. Eng. J. Med. 292:1975;775-780.
24. McCaffrey R., Lillquist A., Sallan S., Cohen E., Osband M. Clinical utility of leukemia cell terminal transferase measurements. Cancer Res. 41:1981;4814-4820.
25. Mercieca J., Matutes E., Dearden C., MacLennan K., Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 12:1994;2588-2593.
26. Müller W. E. G., Seibert G., Beyer R., Breter H. J., Maidhof A., Zahn R. K. Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res. 37:1977;3824-3833.
27. Rai K. R. Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: An intergroup study. Leukemia Lymphoma. 14:1994;107-108.
28. Schabel F. M. Jr., Trader M. W., Laster W. R. Increased therapeutic activity of 9-β-D. Proc. Am. Assoc. Cancer Res. ASCO. 17:1976;46.
29. Williamson J. Cordycepin, an antitumor antibiotic with trypanocidal properties. Trans. Roy. Soc. Trop. Med. Hyg. 60:1966;8-9.
30. Witte R. S., Walsh C., Fisher H., Okem M. M., Reding D. J., Trump D. L. Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. Invest. New Drugs. 10:1992;49-50.